Estrogen receptor beta repurposes EZH2 to suppress oncogenic NFκB/p65 signaling in triple negative breast cancer

Triple Negative Breast Cancer (TNBC) accounts for 15–20% of all breast cancer cases, yet is responsible for a disproportionately high percentage of breast cancer mortalities. Thus, there is an urgent need to identify novel biomarkers and therapeutic targets based on the molecular events driving TNBC...

Descripción completa

Detalles Bibliográficos
Autores principales: Aspros, Kirsten G. M., Carter, Jodi M., Hoskin, Tanya L., Suman, Vera J., Subramaniam, Malayannan, Emch, Michael J., Ye, Zhenqing, Sun, Zhifu, Sinnwell, Jason P., Thompson, Kevin J., Tang, Xiaojia, Rodman, Esther P. B., Wang, Xiyin, Nelson, Adam W., Chernukhin, Igor, Hamdan, Feda H., Bruinsma, Elizabeth S., Carroll, Jason S., Fernandez-Zapico, Martin E., Johnsen, Steven A., Kalari, Krishna R., Huang, Haojie, Leon-Ferre, Roberto A., Couch, Fergus J., Ingle, James N., Goetz, Matthew P., Hawse, John R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854734/
https://www.ncbi.nlm.nih.gov/pubmed/35177654
http://dx.doi.org/10.1038/s41523-022-00387-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854734/
https://www.ncbi.nlm.nih.gov/pubmed/35177654
http://dx.doi.org/10.1038/s41523-022-00387-0

Ejemplares similares